Travaux scientifiques

Doç. Dr. Dilek Erdem

90 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma

    Immunotherapy, 2026

    DOI 10.1080/1750743x.2026.2722548 PMID 42683510 Texte intégral en libre accèsSource : OpenAlex

  2. Abstract PS5-02-08: Impact of Prior T-DM1 Exposure on the Efficacy of Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps5-02-08 Source : OpenAlex

  3. Abstract PS5-05-14: Real-world outcomes of trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps5-05-14 Source : OpenAlex

  4. Lung Metastatic Ameloblastoma: A Hidden Cause of Pulmonary Nodules

    Balkan medical journal, 2026

    DOI 10.4274/balkanmedj.galenos.2025.2025-8-6 PMID 40936298 Texte intégral en libre accèsSource : Europe PMC

  5. Abstract PS4-04-11: Statins enhance trastuzumab deruxtecan efficacy: Preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps4-04-11 Source : OpenAlex

  6. First-in-class HIF-2α therapy in genitourinary oncology: Belzutifan from von Hippel–Lindau disease to advanced renal cell carcinoma

    Cancer Chemotherapy and Pharmacology, 2026

    DOI 10.1007/s00280-025-04861-x PMID 41569310 2 citations (OpenAlex) Source : OpenAlex

  7. Efficacy and toxicity outcomes of total neoadjuvant FLOT versus perioperative FLOT in resectable gastric cancer: Results from the Turkish Oncology Gastrointestinal Cancer Working Group.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.2_suppl.414 Source : OpenAlex

  8. Clinical outcomes of adjuvant treatment strategies in locally advanced gastroesophageal and gastric adenocarcinoma with poor pathological response to neoadjuvant FLOT: A Turkish Oncology Group (TOG) study.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.e16150 Texte intégral en libre accèsSource : OpenAlex

  9. Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group

    International Journal of Cancer, 2025

    DOI 10.1002/ijc.70213 PMID 41147655 3 citations (Europe PMC) Source : OpenAlex

  10. Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program

    Future Oncology, 2025

    DOI 10.1080/14796694.2025.2570637 PMID 41103123 Texte intégral en libre accèsSource : OpenAlex

  11. Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-15287-2 PMID 41275151 Texte intégral en libre accèsSource : OpenAlex

  12. HER2 POZITIF METASTATIK MEME KANSERLI HASTALARDA TRASTUZUMAB DERUXTECAN’IN GERÇEK YAŞAM VERILERI: TÜRK ONKOLOJI GRUBU ÇOK MERKEZLI ÇALIŞMASI

    Kocaeli Üniversitesi - AVESİS, 2025

    Source : OpenAlex

  13. ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer

    New England Journal of Medicine, 2025

    DOI 10.1056/nejmoa2511885 PMID 41124204 199 citations (OpenAlex) Source : OpenAlex

  14. 169P: THASSOS-INTL Türkiye subset: Unveiling treatment patterns and clinical outcomes in resectable early-stage NSCLC

    Journal of Thoracic Oncology, 2025

    DOI 10.1016/s1556-0864(25)00363-6 Texte intégral en libre accèsSource : OpenAlex

  15. Can Cytoreductive Nephrectomy Improve Outcomes of Nivolumab Treatment in Patients with Metastatic Clear-Cell Renal Carcinoma?

    Current Oncology, 2024

    DOI 10.3390/curroncol31090384 PMID 39330012 Texte intégral en libre accèsSource : OpenAlex

  16. Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study

    Cancers, 2024

    DOI 10.3390/cancers16122251 PMID 38927957 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  17. Association Between Baseline and Changes in Early Neutrophil-to-Lymphocyte Ratio on Survival in Patients with Metastatic Bladder Carcinoma Treated with Immunotherapy

    Medicina, 2024

    DOI 10.3390/medicina60122103 PMID 39768982 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  18. Immune Checkpoint Blockade Therapies Efficacy and Toxicity in Patients With Impaired Renal Function in Metastatic Bladder Cancer

    Clinical Genitourinary Cancer, 2024

    DOI 10.1016/j.clgc.2024.102228 PMID 39461025 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

  19. Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors

    Clinical Genitourinary Cancer, 2024

    DOI 10.1016/j.clgc.2024.102163 PMID 39126823 1 citation (Europe PMC) Source : ORCID

  20. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.24.01001 PMID 38857463 139 citations (OpenAlex) Texte intégral en libre accèsSource : ORCID

  21. Immune checkpoints blockade therapies' efficacy and toxicity in patients with impaired renal function in metastatic bladder cancer.

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.4_suppl.594 Texte intégral en libre accèsSource : OpenAlex

  22. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

    BMC Cancer, 2023

    DOI 10.1186/s12885-023-10609-8 PMID 36765293 18 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  23. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study

    Journal of Cancer Research and Clinical Oncology, 2023

    DOI 10.1007/s00432-023-04766-3 PMID 37067546 7 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  24. Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study

    Neoplasma, 2023

    DOI 10.4149/neo_2022_221004n984 PMID 36620878 Texte intégral en libre accèsSource : OpenAlex

  25. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

    Acta Oncologica, 2023

    DOI 10.1080/0284186x.2023.2202330 PMID 37083566 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  26. Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice

    Clinical Genitourinary Cancer, 2023

    DOI 10.1016/j.clgc.2022.11.019 PMID 36641357 2 citations (Europe PMC) Source : ORCID

  27. Comparison of objective response rate and long-term overall survival in patients with treated immune checkpoint inhibitors in metastatic urothelial carcinoma.

    Journal of Clinical Oncology, 2023

    DOI 10.1200/jco.2023.41.6_suppl.481 Source : OpenAlex

  28. The Prognostic Significance of Lymphocyte-C-Reactive Protein Ratio in Non-Small Cell Lung Cancer Patien Receiving Immunotherapy

    Eurasian Journal of Medical Investigation, 2023

    DOI 10.14744/ejmi.2023.47013 Source : OpenAlex

  29. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-03984-5 PMID 35381885 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  30. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer

    Journal of Cancer Research and Therapeutics, 2022

    DOI 10.4103/jcrt.jcrt_1104_21 PMID 36510987 6 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  31. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-04252-2 PMID 36048274 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  32. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

    Future Oncology, 2022

    DOI 10.2217/fon-2022-0083 PMID 35734870 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  33. Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study

    Journal of Chemotherapy, 2022

    DOI 10.1080/1120009x.2022.2073159 PMID 35579894 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  34. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-04087-x PMID 35689097 11 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  35. Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.2022.40.16_suppl.e12610 2 citations (OpenAlex) Source : OpenAlex

  36. Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

    Bursa Uludag University - AVESIS, 2022

    Source : OpenAlex

  37. Discoidin domain receptor 1 as a promising biomarker for high-grade gliomas

    Journal of Cancer Research and Therapeutics, 2022

    DOI 10.4103/jcrt.jcrt_708_21 PMID 37147958 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  38. Diffusion-Weighted Imaging of Brain Metastasis: Correlation of MRI Parameters with Histologic Type

    Turkish neurosurgery, 2022

    DOI 10.5137/1019-5149.jtn.32084-20.4 PMID 34542898 10 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  39. Effects of Cytoreductive Nephrectomy on Nivolumab Outcomes in Patients with Metastatic Clear Cell Renal Carcinoma: A Retrospective Observational Real-Life Data of Turkish Oncology Group

    Research Square, 2022

    DOI 10.21203/rs.3.rs-1693977/v1 Texte intégral en libre accèsSource : ORCID

  40. Impact of corona-phobia on attitudes and acceptance towards COVID-19 vaccine among cancer patients: a single-center study

    Future oncology (London, England), 2022

    DOI 10.2217/fon-2021-1015 PMID 34851155 13 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  41. The Percentage of ALK-Positive Cells and the Efficacy of First-Line Alectinib in Advanced Non-small Cell Lung Cancer Is it a novel factor for stratification? (Turkish Oncology Group Study)

    Research Square, 2022

    DOI 10.21203/rs.3.rs-1583429/v1 Texte intégral en libre accèsSource : ORCID

  42. 124P Talazoparib in locally advanced or metastatic breast cancer patients: Experience from an early access program in Turkey

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.03.138 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  43. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study

    Cancer Investigation, 2021

    DOI 10.1080/07357907.2021.2017952 PMID 34894960 3 citations (Europe PMC) Source : OpenAlex

  44. Metastatic cutaneous melanoma epidemiological registry in Turkey: A preliminary evaluation of diagnosis and treatment approaches

    Sakarya Üniversitesi Kurumsal Açık Akademik Arşivi, 2021

    Source : OpenAlex

  45. Metastatic cutaneous melanoma epidemiological registry in Turkey: A preliminary evaluation of diagnosis and treatment approaches

    Bursa Uludag University - AVESIS, 2021

    Source : OpenAlex

  46. Ixabepilone in metastatic breast cancer: Real-world experience

    Journal of Oncological Science, 2021

    DOI 10.37047/jos.2021-81340 3 citations (OpenAlex) Texte intégral en libre accèsSource : ORCID

  47. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab

    International Journal of Clinical Oncology, 2021

    DOI 10.1007/s10147-021-01936-6 PMID 34023933 14 citations (Europe PMC) Source : ORCID

  48. Real Life Experience of Patients With Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma Treated With Neoadjuvant Chemotherapy: a Turkish Oncology Group Study

    Research Square, 2021

    DOI 10.21203/rs.3.rs-884239/v1 Texte intégral en libre accèsSource : ORCID

  49. Pulmonary langerhans cell histiocytosis: Can it originate from chest trauma?

    Archives of Trauma Research, 2021

    DOI 10.4103/atr.atr_85_20 Texte intégral en libre accèsSource : OpenAlex

  50. Evaluation of the Relationship between Antioxidant Gene Polymorphisms (Endothelial Nitric Oxide Synthase, Myeloperoxidase, Uncoupling Protein 2) and Breast Cancer

    Eurasian Journal of Medicine and Oncology, 2020

    DOI 10.14744/ejmo.2020.99886 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex